Healthcare >> CEO Interviews >> June 1, 2009
JAMES HOWARD-TRIPP is President and Chief Executive Officer of Labopharm Inc.
His career in the pharmaceutical industry spans more than 25 years and three
continents. His diverse roles in pharma have included responsibilities for
research and development, manufacturing (including quality assurance and quality
control), sales and sales management, marketing management at both the domestic
and international levels, as well as strategic planning and portfolio
management. His business development activities have included acquisitions,
mergers, divestitures and licensing, as well as the negotiation of co-
development and co-selling agreements. Prior to joining Labopharm, he was Senior
Vice President, Operations with Allelix Biopharmaceuticals (now NPS Allelix) and
also President and CEO of its subsidiary, Allelix Neuroscience. Before that, he
was Vice President, Business Development for Wyeth-Ayerst Canada, with
responsibility for licensing and acquisitions, new product development and
health economics. He has also held positions with Miles Laboratories (now
Bayer), Roussel Uclaf (now sanofi-aventis), and G.D. Searle (now Pfizer). Profile
Mr. Howard-Tripp: Labopharm is a specialty pharma company. We are based off
novel drug delivery technology. We take existing
